Drug intelligence / Profile preview

AVI002

Development stage: Preclinical
Lead developer: Avipero
Modality: Small Molecules
Administration: Intranasal

Overview

AVI002 is a small molecule modulator of Beta1 integrin (ITGB1) currently in the discovery stage at Avipero. It is being developed to target cellular senescence and promote anti-aging effects. Beta1 integrin is a key cell surface receptor involved in cell-matrix interactions and signaling pathways that regulate cell survival and aging. By modulating this target, AVI002 aims to address the accumulation of senescent cells and their deleterious effects on tissue function, potentially offering a therapeutic approach for various age-related conditions.

Targets

ITGB1 (Integrin beta-1)

Beyond the preview

Go deeper on AVI002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI002.

Explore the full profile